These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 22238246

  • 21. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.
    Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, Boige V, Assenat E, Kang YK, Lim HY, Walters I, Llovet JM.
    J Hepatol; 2017 Jun; 66(6):1166-1172. PubMed ID: 28131794
    [Abstract] [Full Text] [Related]

  • 22. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma.
    Shao YY, Lin ZZ, Hsu C, Lee KD, Hsiao CH, Lu YS, Huang CC, Shen YC, Hsu CH, Cheng AL.
    Oncology; 2012 Jun; 82(1):59-66. PubMed ID: 22310088
    [Abstract] [Full Text] [Related]

  • 23. Complete remission of hepatocellular carcinoma after transarterial Chemoembolization combined with brivanib.
    Jia J, Qi X, Bai W, Yuan J, Han G.
    J Cancer Res Ther; 2014 Jun; 10(4):1112-4. PubMed ID: 25579566
    [Abstract] [Full Text] [Related]

  • 24. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
    Prete SD, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, Piai G, Febbraro A, Tarantino L, Capasso E, Palmieri G, Guarrasi R, Bianco M, Mamone R, Savastano C, Pisano A, Vincenzi B, Sabia A, D'Agostino A, Faiola V, Addeo R.
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):837-44. PubMed ID: 20041325
    [Abstract] [Full Text] [Related]

  • 25. Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma: A case report.
    Zhu H, Zhang C, Yang X, Yi C.
    Medicine (Baltimore); 2019 Mar; 98(10):e14823. PubMed ID: 30855507
    [Abstract] [Full Text] [Related]

  • 26. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Blumenschein GR, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M.
    J Clin Oncol; 2009 Sep 10; 27(26):4274-80. PubMed ID: 19652055
    [Abstract] [Full Text] [Related]

  • 27. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma.
    Petrini I, Lencioni M, Ricasoli M, Iannopollo M, Orlandini C, Oliveri F, Bartolozzi C, Ricci S.
    Cancer Chemother Pharmacol; 2012 Mar 10; 69(3):773-80. PubMed ID: 22033636
    [Abstract] [Full Text] [Related]

  • 28. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
    Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP.
    J Clin Oncol; 2009 Sep 20; 27(27):4462-8. PubMed ID: 19652060
    [Abstract] [Full Text] [Related]

  • 29. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience.
    Montella L, Addeo R, Caraglia M, Faiola V, Guarrasi R, Vincenzi B, Palmeri A, Capasso E, Nocera V, Tarantino L, Ariete M, Martorelli A, Del Prete S.
    Oncol Rep; 2008 Aug 20; 20(2):385-90. PubMed ID: 18636202
    [Abstract] [Full Text] [Related]

  • 30. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial.
    Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, Matsuzawa Y.
    Br J Cancer; 2001 Apr 06; 84(7):886-91. PubMed ID: 11286466
    [Abstract] [Full Text] [Related]

  • 31. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR.
    J Clin Gastroenterol; 2009 Apr 06; 43(5):489-95. PubMed ID: 19247201
    [Abstract] [Full Text] [Related]

  • 32. A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization.
    Tanaka T, Ikeda M, Okusaka T, Ueno H, Morizane C, Ogura T, Hagihara A, Iwasa S.
    Cancer Chemother Pharmacol; 2008 Apr 06; 61(4):683-8. PubMed ID: 17541589
    [Abstract] [Full Text] [Related]

  • 33. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
    Lin AY, Brophy N, Fisher GA, So S, Biggs C, Yock TI, Levitt L.
    Cancer; 2005 Jan 01; 103(1):119-25. PubMed ID: 15565573
    [Abstract] [Full Text] [Related]

  • 34. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
    Miyahara K, Nouso K, Tomoda T, Kobayashi S, Hagihara H, Kuwaki K, Toshimori J, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Yamamoto K.
    J Gastroenterol Hepatol; 2011 Nov 01; 26(11):1604-11. PubMed ID: 22011296
    [Abstract] [Full Text] [Related]

  • 35. Characterization of brivanib therapy response in hepatocellular carcinoma xenografts using ¹H HR-MAS spectroscopy and histopathology.
    Yang J, Song KD, Kim JH, Im GH, Yoon S, Namgung M, Hwang JH, Lee JH, Choi D.
    Mol Med Rep; 2013 Nov 01; 8(5):1425-31. PubMed ID: 24064967
    [Abstract] [Full Text] [Related]

  • 36. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.
    Jonker DJ, Rosen LS, Sawyer MB, de Braud F, Wilding G, Sweeney CJ, Jayson GC, McArthur GA, Rustin G, Goss G, Kantor J, Velasquez L, Syed S, Mokliatchouk O, Feltquate DM, Kollia G, Nuyten DSA, Galbraith S.
    Ann Oncol; 2011 Jun 01; 22(6):1413-1419. PubMed ID: 21131369
    [Abstract] [Full Text] [Related]

  • 37. Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology.
    Gong J, Gan J, Masson E, Syed S, Xia YQ, Williams D, Pursley J, Jemal M, Humphreys WG, Iyer RA.
    Drug Metab Dispos; 2012 Dec 01; 40(12):2374-80. PubMed ID: 22983304
    [Abstract] [Full Text] [Related]

  • 38. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
    Baek KK, Kim JH, Uhm JE, Park SH, Lee J, Park JO, Park YS, Kang WK, Lim HY.
    Oncology; 2011 Dec 01; 80(3-4):167-74. PubMed ID: 21701230
    [Abstract] [Full Text] [Related]

  • 39. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.
    Boige V, Raoul JL, Pignon JP, Bouché O, Blanc JF, Dahan L, Jouve JL, Dupouy N, Ducreux M, Fédération Francophone de Cancérologie Digestive.
    Br J Cancer; 2007 Oct 08; 97(7):862-7. PubMed ID: 17876335
    [Abstract] [Full Text] [Related]

  • 40. High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy.
    Shao YY, Lin ZZ, Chen TJ, Hsu C, Shen YC, Hsu CH, Cheng AL.
    Oncology; 2011 Oct 08; 81(2):98-103. PubMed ID: 21986371
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.